Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases
Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases
This Competitive Intelligence report about Bispecific Antibodies for Immuno-Oncology & Other Diseases evaluates the landscape of investigational bispecific therapeutic antibodies for treatment of cancer, inflammatory & autoimmune diseaseas as well as cardiometabolic, infectious, neurologic and ophthalmic diseases as of June 2019.
At present, only two bispecific therapeutic monoclonal antibodies are on the market, one for leukemia and one for hemophilia. La Merie Publishing conducted a search for bispecific monoclonal antibodies (and some multimeric proteins) in R&D. The search identified 271 unique bispecific antibody-based constructs in active R&D (excluding discontinued developments of bispecifics). Of the 110 clinical stage bispecific antibodies, 50% are used for redirection of T-cells to a tumor target. More than 85% of the clinical stage bispecific molecules are in development for treatment of cancer. The combination of immune checkpoint inhibitor and/or activator targets is a strongly emerging use of the bispecific antibody technology. The traditonal application of bispecifics for targeting two tumor-associated antigens (or epitopes) and/or growth factors is a field with strong clinical activities, but the non-clinical pipeline is relatively empty compared with immuno-oncology bispecifics (11 vs 48 projects).
The report highlights the use of bispecific antibody technology for generation of
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence report about Bispecific Antibodies for Immuno-Oncology & Other Diseases evaluates the landscape of investigational bispecific therapeutic antibodies for treatment of cancer, inflammatory & autoimmune diseaseas as well as cardiometabolic, infectious, neurologic and ophthalmic diseases as of June 2019.
At present, only two bispecific therapeutic monoclonal antibodies are on the market, one for leukemia and one for hemophilia. La Merie Publishing conducted a search for bispecific monoclonal antibodies (and some multimeric proteins) in R&D. The search identified 271 unique bispecific antibody-based constructs in active R&D (excluding discontinued developments of bispecifics). Of the 110 clinical stage bispecific antibodies, 50% are used for redirection of T-cells to a tumor target. More than 85% of the clinical stage bispecific molecules are in development for treatment of cancer. The combination of immune checkpoint inhibitor and/or activator targets is a strongly emerging use of the bispecific antibody technology. The traditonal application of bispecifics for targeting two tumor-associated antigens (or epitopes) and/or growth factors is a field with strong clinical activities, but the non-clinical pipeline is relatively empty compared with immuno-oncology bispecifics (11 vs 48 projects).
The report highlights the use of bispecific antibody technology for generation of
- T-Cell Redirecting Bispecific Antibodies
- Bispecific Natural Killer (NK) Cell Redirecting Antibodies
- Bispecific T-Cell Engaging, Conditional Costimulatory Antibodies
- Bispecific Immuno-Oncology Antibodies
- Bispecific Tumor Associated Antigen (TAA)/Growth Factor Targeted Antibodies
- Bispecific Antibodies for Non-Cancer Indications
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.
1) T-CELL REDIRECTING BISPECIFIC ANTIBODIES
Targeting BCMA
Targeting CD20
Targeting CD19
Targeting CD33
Targeting CD123
argeting PSMA
Targeting Her2
Targeting Mesothelin
Targeting CD38
Targeting EGF-R
Targeting DLL3
Targeting Various Other Cancer Surface Antigens
Targeting Not Disclosed Tumor Associated Antigens
Targeting (Intracellular) peptide/MHC Antigens
Novel Bispecific T-Cell Redirecting Antibody Constructs
Bispecific T-Cell Redirecting Antibodies for Infectious & Other Diseases
2) BISPECIFIC NATURAL KILLER (NK) CELL REDIRECTING ANTIBODIES
3) BISPECIFIC T-CELL ENGAGING, CONDITIONAL COSTIMULATORY ANTIBODIES
Bispecific, Tumor-Targeted, Conditional 4-1BB Costimulatory Antibodies
Bispecific, Tumor-Targeted, Conditional CD40 Costimulatory Antibodies
Bispecific, Tumor-Targeted, Conditional CD28 or OX40 Costimulatory Antibodies
Bispecific, Dual Costimulatory Antibodies
4) BISPECIFIC IMMUNO-ONCOLOGY ANTIBODIES
Bispecific, Tumor-Targeted Checkpoint Inhibitor Antibodies
Bispecific Checkpoint Inhibitor & Costimulator Antibodies
Bispecific CD47 Tumor Microenvironment (TME) Targeted Antibodies
Other Bispecific, Tumor Microenvironment (TME) Targeted Antibodies
Bispecific, Dual PD-1 & PD-L1 Checkpoint Inhibitor Antibodies
Bispecific, Dual PD-1/PD-L1 & CTLA-4 Checkpoint Inhibitor Antibodies
Bispecific, Dual PD-1 & LAG-3 Checkpoint Inhibitor Antibodies
Bispecific, Dual PD-L1/CTLA-4 & LAG-3 Checkpoint Inhibitor Antibodies
Bispecific, PD-1/PD-L1/CTLA-4 & TIM-3 or GITR Checkpoint Inhibitor Antibodies
Bispecific, Not Specified Immuno-Oncology Antibodies
5) BISPECIFIC TUMOR ASSOCIATED ANTIGEN (TAA) / GROWTH FACTOR TARGETED ANTIBODIES –
Bispecific Her2-Targeted Antibodies
Bispecific VEGF-Targeted Antibodies
Other Bispecific TAA-Targeted Antibodies
6) BISPECIFIC ANTIBODIES FOR NON-CANCER INDICATIONS
Bispecific Inflammatory & Autoimmune Disease Antibodies
Bispecific Cardiometabolic Antibodies
Bispecific Ophthalmic Disease Antibodies
Bispecific Neurologic Disease Antibodies
Bispecific Infectious Disease Antibodies
Bispecific Antibodies For Targeted Delivery
Targeting BCMA
Targeting CD20
Targeting CD19
Targeting CD33
Targeting CD123
argeting PSMA
Targeting Her2
Targeting Mesothelin
Targeting CD38
Targeting EGF-R
Targeting DLL3
Targeting Various Other Cancer Surface Antigens
Targeting Not Disclosed Tumor Associated Antigens
Targeting (Intracellular) peptide/MHC Antigens
Novel Bispecific T-Cell Redirecting Antibody Constructs
Bispecific T-Cell Redirecting Antibodies for Infectious & Other Diseases
2) BISPECIFIC NATURAL KILLER (NK) CELL REDIRECTING ANTIBODIES
3) BISPECIFIC T-CELL ENGAGING, CONDITIONAL COSTIMULATORY ANTIBODIES
Bispecific, Tumor-Targeted, Conditional 4-1BB Costimulatory Antibodies
Bispecific, Tumor-Targeted, Conditional CD40 Costimulatory Antibodies
Bispecific, Tumor-Targeted, Conditional CD28 or OX40 Costimulatory Antibodies
Bispecific, Dual Costimulatory Antibodies
4) BISPECIFIC IMMUNO-ONCOLOGY ANTIBODIES
Bispecific, Tumor-Targeted Checkpoint Inhibitor Antibodies
Bispecific Checkpoint Inhibitor & Costimulator Antibodies
Bispecific CD47 Tumor Microenvironment (TME) Targeted Antibodies
Other Bispecific, Tumor Microenvironment (TME) Targeted Antibodies
Bispecific, Dual PD-1 & PD-L1 Checkpoint Inhibitor Antibodies
Bispecific, Dual PD-1/PD-L1 & CTLA-4 Checkpoint Inhibitor Antibodies
Bispecific, Dual PD-1 & LAG-3 Checkpoint Inhibitor Antibodies
Bispecific, Dual PD-L1/CTLA-4 & LAG-3 Checkpoint Inhibitor Antibodies
Bispecific, PD-1/PD-L1/CTLA-4 & TIM-3 or GITR Checkpoint Inhibitor Antibodies
Bispecific, Not Specified Immuno-Oncology Antibodies
5) BISPECIFIC TUMOR ASSOCIATED ANTIGEN (TAA) / GROWTH FACTOR TARGETED ANTIBODIES –
Bispecific Her2-Targeted Antibodies
Bispecific VEGF-Targeted Antibodies
Other Bispecific TAA-Targeted Antibodies
6) BISPECIFIC ANTIBODIES FOR NON-CANCER INDICATIONS
Bispecific Inflammatory & Autoimmune Disease Antibodies
Bispecific Cardiometabolic Antibodies
Bispecific Ophthalmic Disease Antibodies
Bispecific Neurologic Disease Antibodies
Bispecific Infectious Disease Antibodies
Bispecific Antibodies For Targeted Delivery